FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including a compound of an antibody-drug conjugate for the treatment of solid tumors and hematological malignant neoplasms and a pharmaceutical composition for the treatment of solid tumors and hematological malignant tumors. In one of embodiments, the compound of an antibody-drug conjugate contains a drug conjugated using a linker in a site-specific way with an antibody or its antigen-binding fragment that bind to a target antigen expressed by a tumor cell through embedded cysteine in the specified antibody or its antigen-binding fragment at position 40 or 41 of a light chain according to Kabat numeration.
EFFECT: invention expands the arsenal of means for the treatment of solid tumors and hematological malignant neoplasms.
13 cl, 4 dwg, 7 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DOUBLE CONJUGATION FOR OBTAINING ANTIBODY-DRUG CONJUGATES | 2018 |
|
RU2771310C2 |
| ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER DISEASES | 2019 |
|
RU2799547C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| HUMANIZED ANTI-PSMA ANTIBODIES | 2019 |
|
RU2794450C2 |
| ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | 2016 |
|
RU2757815C2 |
| ANTIBODIES AGAINST CD79b, DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2805251C2 |
| ANTI-CD79B ANTIBODIES, IMMUNOCONJUGATES AND METHODS FOR THEIR USE | 2019 |
|
RU2791984C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| ANTIBODIES AGAINST EDB AND ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2758632C2 |
| SITE-SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2745565C2 |
